ABSTRACT
Background and Aim(s) This study retrospectively assessed the prevalence of TB and HIV/AIDS co-infection among patients that attended the Directly Observed Treatment Short-course (DOTS) centers in Anambra State, Southeast, Nigeria, between 2013 and 2017.
Methods The study adopted a descriptive and retrospective epidemiological survey design. A total of 1443 case files of patients aged 15 to 60 who were treated in DOTS centers selected from Anambra State’s 21 Local Government Areas between 2013 and 2017 were investigated. The uniform data form, a standardized instrument used in Anambra State’s health facilities for data collection, was used to collect data from case files of all those identified as co-infected with TB and HIV/AIDS.
Results The mean prevalence rate of TB and HIV/AIDS co-infection in the state during the five-year period (2013–2017) was 20%. The highest annual prevalence of TB and HIV/AIDS co-infection was recorded in 2014 (23.84%). The state’s prevalence of TB and HIV/AIDS co-infection increased dramatically from 13.17% in 2013 to 23.84% in 2014, followed by a slight downward trend to 22.80% in 2015, 20.17% in 2016, and 20.03% in 2017. In terms of gender, age, marital status, and occupation, females (59.5%), those aged 15 to 25 years (30.7%), married people (43.9%), and traders/business owners (50.7%), respectively, had the highest rates of tuberculosis and HIV/AIDS co-infection during the study period.
Conclusion The findings of this study show that young people, females, married people, and traders/business owners appear to be the most vulnerable groups affected by TB and HIV/AIDS co-infection, accounting for the majority of the disease burden in the state. To address the high prevalence of TB and HIV/AIDS co-infection in the Anambra State, novel intervention and control programs should be developed and implemented, and existing intervention frameworks should be strengthened.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Board of Anambra State Ministry of Health gave ethical approval for this work. A copy of this document will be provided on request.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Error in the abstract has been corrected. The referencing method has been changed. In addition, a missing reference has been included in the reference section.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
